Table 1—

Sociodemographic, nonadherence, and clinic characteristics

Characteristics
n677
Age (years) (means ± SD)63.9 ± 10.6
Women (%)53.2
Race (%)
    Caucasian53.3
    African American41.4
    Other5.3
Clinical outcomes [means ± SD (n)]
    HbA1c (%)8.0 ± 1.4 (675)
    LDL cholesterol (mg/dl)116.9 ± 30.7 (659)
    Blood pressure (mmHg)138.5 ± 12.8/80.0 ± 7.2 (674)
    BMI (kg/m2)33.1 ± 6.8 (560)
Treatments during each study year [% (n)]
    Metformin45.5 (308)
    Statins42.4 (287)
    ACE inhibitors56.7 (384)
Number of drugs used [means (median)]
    Oral antidiabetic drugs (among metformin users)2.1 (2)
    Lipid-lowering drugs (among statin users)1.1 (1)
    Antihypertensive drugs (among ACE inhibitor users)2.6 (2)
Nonadherence indices (CMG percentages)* [median (means ± SD)]
    Metformin16.8 (21.6 ± 18.9)
    Statins13.2 (18.4 ± 17.7)
    ACE inhibitors7.3 (13.7 ± 16.1)
Prevalence of nonadherence (%)
    Metformin43
    Statins36
    ACE inhibitors23
  • *

    * CMG indicates the proportion of days with gaps in medication refills over the days in the observation period.

  • Nonadherence is defined as CMG >20%.